Oryzon Genomics (ORY) investor relations material

Executive summary

• Positive clinical data for iadademstat in first-line AML: 100% ORR, 89% CRc, 78% CR, including patients with adverse mutations; favorable safety profile maintained.

• Iadademstat + gilteritinib in FLT3-mutated relapsed/refractory AML showed 67% CRc and favorable safety in heavily pre-treated patients.

• Enrollment began for Phase II trial of iadademstat in essential thrombocythemia; ongoing studies in myeloproliferative neoplasms, SCD, and SCLC.

• Vafidemstat advanced toward Phase III in BPD aggression; U.S. patent granted for BPD use, extending IP protection to 2043.

• Cash position at June 30, 2026: $16.7M, excluding €12M ($13.7M) raised post-quarter; €25M future investment commitment from COFIDES.

Financial highlights

• R&D expenses: $6.3M for Q2 2026, $11.4M for H1 2026, up from $3.0M and $5.8M in 2025.

• G&A expenses: $1.3M for Q2 2026, $2.8M for H1 2026, similar to prior year.

• Net loss: $1.6M for Q2 2026, $3.6M for H1 2026, compared to $1.7M and $3.4M in 2025.

• Cash and equivalents: $16.7M as of June 30, 2026; total assets $160.2M; equity $136.4M.

• No collaboration revenue reported; loss per share -$0.02 for H1 2026.

Outlook and guidance

• Final ALICE-2 and FRIDA data expected by year-end; potential FDA engagement for registrational AML study in 2027.

• Continued advancement of vafidemstat in BPD, ASD, and schizophrenia; Phase III and II trials planned or ongoing.

• Additional financial flexibility from recent capital raise and COFIDES commitment to support clinical pipeline.